Mono-PEGylated radix ophiopogonis polysaccharide for the treatment of myocardial ischemia

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 629-636

  Sun, GuiLan ^a   Lin, Xiao ^a   Shen, Lan ^a   Wu, Fei ^a   Xu, DeSheng ^a   Ruan, KeFeng ^a   Feng, Yi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Characterization; Myocardial ischemia; Polyethylene glycol; Polysaccharide; Radix Ophiopogonis

Indexed keywords

OPHIOPOGON ROOT; POLYSACCHARIDE; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COLORIMETRY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; GEL PERMEATION CHROMATOGRAPHY; GLOMERULUS FILTRATION RATE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART WEIGHT; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; MEDICATION COMPLIANCE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REFRACTION INDEX; SYSTEMIC CIRCULATION; THERAPY EFFECT;

EID: 84879475525     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.05.020     Document Type: Article

References (40)

1. Banka, N., Anand, I.S., Nirankari, O.P., Gulati, S., Sharma, P.L., Chakravarti, R.N., Wahi, P.L., 1982. Macroscopic and microscopic measurement of myocardial infarct size. A comparison. Res. Exp. Med. (Berl) 181, 125-133. (Pubitemid 12004475)
2. Charman, S.A., Segrave, A.M., Edwards, G.A., Porter, C.J.H., 2000. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci. 89, 168-177. (Pubitemid 30120797)
3. Chiu, H.C., Konak, C., Kopeckova, P., Kopecek, J., 1994. Enzymatic degradation of poly(ethylene glycol)-modified dextrans. J. Bioactive Compat. Polym. 9, 388-410.
4. DeFrees, S., Wang, Z.G., Xing, R., Scott, A.E., Wang, J., Zopf, D., Gouty, D.L., Sjoberg, E.R., Panneerselvam, K., Brinkman-Van der Linden, E.C., Bayer, R.J., Tarp, M.A., Clausen, H., 2006. Glyco PEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16, 833-843. (Pubitemid 44390927)
5. Duncan, R., Veronese, F.M., 2009. PEGylated protein conjugates: a new class of therapeutics for the 21st century. In: Veronese, F.M. (Ed.), PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhäuser Verlag, Basel, Switzerland, pp. 1-9.
6. Dust, J.M., Fang, Z.H., Harris, J.M., 1990. Proton NMR characterization of poly(ethylene glycols) and derivatives. Macromolecules 23, 3742-3746. (Pubitemid 20732033)
7. Fee, C.J., 2009. Protein conjugates purification and characterization. In: Veronese, F.M. (Ed.), PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhäuser Verlag, Basel, Switzerland, pp. 113-125.
8. Hinds, K.D., Kim, S.W., 2002. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54, 505-530. (Pubitemid 34615546)
9. Huh, K.M., Ooya, T., Lee, W.K., Sasaki, S., Kwon, I.C., Jeong, S.Y., Yui, N., 2001. Supramolecular-structured hydrogels showing a reversible phase transition by inclusion complexation between poly(ethylene glycol) grafted dextran and acyclodextrin. Macromolecules 34, 8657-8662. (Pubitemid 34011391)
10. Kang, J.S., DeLuca, P.P., Lee, K.C., 2009. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 14, 363-380.
11. Lin, X., Xu, D.S., Feng, Y., Shen, L., 2005. Determination of Ophiopogon japonicus polysaccharide in plasma by HPLC with modified postcolumn fluorescence derivatization. Anal. Biochem. 342, 179-185. (Pubitemid 40884564)
12. Lin, X., Wang, S., Jiang, Y., Wang, Z.J., Sun, G.L., Xu, D.S., Feng, Y., Shen, L., 2010a. Poly(ethylene glycol)-Radix Ophiopogonis polysaccharide conjugates: preparation, characterization, pharmacokinetics and in vitro bioactivity. Eur. J. Pharm. Biopharm. 76, 230-237.
13. Lin, X., Wang, Z., Sun, G., Shen, L., Xu, D., Feng, Y., 2010b. A sensitive and specific HPGPC-FD method for the study of pharmacokinetics and tissue distribution of Radix Ophiopogonis polysaccharide in rats. Biomed. Chromatogr. 24, 820-825.
14. Lin, X., Wang, Z.J., Huang, F., Liang, S., Shen, L., Feng, Y., Ruan, K.F., 2011a. Longcirculating delivery of bioactive polysaccharide from Radix Ophiopogonis by PEGylation. Int. J. Nanomed. 6, 2865-2872.
15. Lin, X., Wang, Z.J., Wang, S., Shen, L., Feng, Y., Ruan, K.F., Xu, D.S., 2011b. Comparison of tissue distribution of a PEGylated Radix Ophiopogonis polysaccharide in mice with normal and ischemic myocardium. Eur. J. Pharm. Biopharm. 79, 621-626.
16. Lukyanov, A.N., Sawant, R.M., Hartner, W.C., Torchilin, V.P., 2004. PEGylated dextran as long-circulating pharmaceutical carrier. J. Biomater. Sci. Polym. Ed. 15, 621-630. (Pubitemid 38832585)
17. Manjula, B.N., Tsai, A., Upadhya, R., Perumalsamy, K., Smith, P.K., Malavalli, A., Vandegriff, K., Winslow, R.M., Intaglietta, M., Prabhakaran, M., Friedman, J.M., Acharya, A.S., 2003. Site-specific PEGylation of hemoglobin at Cys-93 (β): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug. Chem. 14, 464-472. (Pubitemid 36348671)
18. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J.M., Veronese, F.M., 1995. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6, 62-69.
19. Mueller, T.M., Marcus, M.L., Mayer, H.E., Williams, J.K., Hermsmeyer, K., 1981. Liposome concentration in canine ischemic myocardium and depolarized myocardial cells. Circ. Res. 49, 405-415. (Pubitemid 11053300)
20. Pasut, G., Veronese, F.M., 2007. Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 32, 933-961. (Pubitemid 47198290)
21. Pasut, G., Veronese, F.M., 2009. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today 45, 687-695.
22. Piquet, G., Gatti, M., Barbero, L., Traversa, S., Caccia, P., Esposito, P., 2002. Set-up of large laboratory-scale chromatographic separations of poly(ethylene glycol) derivatives of the growth hormone-releasing factor 1-29 analogue. J. Chromatogr. A 944, 141-148. (Pubitemid 34075438)
23. Reddy, K.R., Modi, M.W., Pedder, S., 2002. Use of peginterferon α2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54, 571-586. (Pubitemid 34615548)
24. Rogge, T.M., Stevens, C.V., Vandamme, A., Booten, K., Levecke, B., D'Hooge, C., Haelterman, B., Corthouts, J., 2005. Application of ethoxylated inulin in water-blown polyurethane foams. Biomacromolecules 6, 1992-1997. (Pubitemid 41056942)
25. Sato, H., 2002. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 54, 487-504. (Pubitemid 34615545)
26. Schlesinger, N., Yasothan, U., Kirkpatrick, P., 2011. Pegloticase. Nat. Rev. Drug Discov. 10, 17-18.
27. Scott, R.C., Crabbe, D., Krynska, B., Ansari, R., Kiani, M.F., 2008. Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin. Drug Deliv. 5, 459-470. (Pubitemid 351721724)
28. Sun, G.L., Lin, X., 2010. Mechanisms and strategies for targeting drugs to myocardial ischemic regions. Acta Pharm. Sin. 45, 827-832.
29. Sun, G., Lin, X., Wang, Z., Feng, Y., Xu, D., Shen, L., 2011. PEGylated inulin as longcirculating pharmaceutical carrier. J. Biomater. Sci. Polym. Ed. 22, 429-441.
30. Sun, G.L., Lin, X., Hong, Y.L., Feng, Y., Ruan, K.F., Xu, D.S., 2012. PEGylation for drug delivery to ischemic myocardium: pharmacokinetics and cardiac distribution of poly(ethylene glycol)s in mice with normal and ischemic myocardium. Eur. J. Pharm. Sci. 46, 545-552.
31. Supersaxo, A., Hein, W., Gallati, H., Steffen, H., 1988. Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm. Res. 5, 472-476.
32. Supersaxo, A., Hein, W.R., Steffen, H., 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7, 167-169. (Pubitemid 20208069)
33. Torchilin, V.P., 1995. Targeting of drugs and drug carriers within the cardiovascular system. Adv. Drug Deliv. Rev. 17, 75-101.
34. 1 and bFGF expression and augments survival and angiogenesis in the ischemic heart. Glycobiology 20, 473-484.
35. Wang, Z.J., Lin, X., Shen, L., Feng, Y., Xu, D.S., Ruan, K.F., 2011. Pharmacokinetics of a long-circulating PEGylated Radix Ophiopogonis polysaccharide. Acta Pharmaceut. Sin. 46, 1257-1261.
36. Webster, R., Elliott, V., Park, B.K., Walker, D., Hankin, M., Taupin, P., 2009. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese, F.M. (Ed.), PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhäuser Verlag, Basel, Switzerland, pp. 127-146.
37. World Health Organization. Health Statistics and Informatics Department, 2011. Causes of Death 2008 Summary Tables. WHO, Geneva.
38. Wong, S.S., 1991. Reactive groups of proteins and their modifying agents. In: Wong, S.S. (Ed.), Chemistry of Protein Conjugation and Cross-Linking. CRC, Boston, p. 13.
39. Xu, D.S., Feng, Y., Lin, X., Deng, H.L., Fang, J.N., Dong, Q., 2005. Isolation, purification and structural analysis of a polysaccharide MDG-1 from Ophiopogon Japonicus. Acta Pharmaceut. Sin. 40, 636-639. (Pubitemid 41260343)
40. Zheng, Q., Feng, Y., Xu, D.S., Lin, X., Chen, Y.Z., 2009. Influence of sulfation on antimyocardial ischemic activity of Ophiopogon japonicus polysaccharide. J. Asian Nat. Prod. Res. 11, 306-321.